Literature DB >> 16782337

Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.

David Ellis1, Kelli L Kuhen, Beth Anaclerio, Baogen Wu, Karen Wolff, Hong Yin, Badry Bursulaya, Jeremy Caldwell, Donald Karanewsky, Yun He.   

Abstract

A novel series of quinolones was discovered as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) using a structure-based approach. The lead quinolones exhibited single digit nanomolar potency in the HIV-1 replication assays. The preliminary SAR of these quinolones was also established via systematic structural modifications. These novel and potent quinolones could serve as advanced leads for further optimization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782337     DOI: 10.1016/j.bmcl.2006.05.073

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Novel twisted intramolecular charge transfer (TICT) extended fluorescent styryl derivatives containing quinoline electron releasing moiety.

Authors:  Mininath S Deshmukh; Nagaiyan Sekar
Journal:  J Fluoresc       Date:  2014-10-14       Impact factor: 2.217

2.  Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors.

Authors:  Brett Hopkins; Hongjun Zhang; Indu Bharathan; Derun Li; Qinglin Pu; Hua Zhou; Theodore A Martinot; Xavier Fradera; Alfred Lammens; Charles A Lesburg; Ryan D Cohen; Jeanine Ballard; Ian Knemeyer; Karin Otte; Stella Vincent; J Richard Miller; Nicolas Solban; Mangeng Cheng; Prasanthi Geda; Nadya Smotrov; Xuelei Song; David Jonathan Bennett; Yongxin Han
Journal:  ACS Med Chem Lett       Date:  2021-08-18       Impact factor: 4.632

3.  Synthesis of highly enantioenriched 3,4-dihydroquinolin-2-ones by 6-exo-trig radical cyclizations of axially chiral alpha-halo-ortho-alkenyl anilides.

Authors:  David B Guthrie; Steven J Geib; Dennis P Curran
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.